Open in web browser

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

Cholesterol drugs

6 reasons cholesterol drug guidelines must change

By Christine Blank
In a commentary published online first August 10 in the Journal of the American Medical Association (JAMA), experts from CVS Health Research Institute encouraged the cardiology community to review and reconsider current treatment guidelines for the management of high cholesterol. Reasons for changes

Study: Real-world Actemra data show lower rate of some SAEs vs. clinical trials in RA

By Tracey Walker
A study of tocilizumab (Actemra) in the treatment of rheumatoid arthritis (RA), found that the number of serious adverse events (SAEs) found in postmarketing data were similar to other populations from clinical trials and epidemiology data. 5 study take-aways

CONTINUING EDUCATION

Primer on inhalers and nebulizers

This month's CE activity is part of the CPE series, Medication Therapy Management for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to discuss the various types of inhaled devices and educate pharmacists on the techniques for correct device use.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT33-FTX29.

The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php.
All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to
https://web2.uconn.edu/pharmacyce/program_register.php.
For a full list of courses, go to
http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce

EDITOR'S PICK

3 things to remember about naloxone

By Tracey Walker
Nasal naloxone (Indivior) has the potential to be first intranasal naloxone product inthe United States to treat opioid overdose if approved. Read more

August 14, 2015

Related Articles

5 things to know about cholesterol-lowering PCSK9 inhibitors

Actemra gets breakthrough therapy designation for scleroderma

Resources

Get the latest FormularyWatch updates on drug approvals, current studies, and other findings.

Click for the latest Clinical News

Click here to contact Editorial. Sales, Reprints, Classified questions? Click here to contact the Sales Team.

ModernMedicine logo
UBM  logo

UBM MEDICA